Company News

Jellatech Unveils Updated Brand to Showcase Cell-Based Collagen Solutions for Health and Longevity

Jellatech, a US biotech startup pioneering the development of cell-based collagen, announces the launch of its updated brand and website.

As stated by the company, the new rebrand has been designed to showcase its mission to revolutionize biomedical applications with “cutting-edge” human-identical proteins, beginning with Type 1 collagen. Jellatech says these proteins enable breakthroughs in tissue regeneration, injectable aesthetics, cell and gene therapy, and various therapeutic applications.

“We aim to reduce environmental impact and enhance the quality of life for all”

Founder and CEO Stephanie Michelsen told Cultivated X, “Through our market engagement, we identified a critical unmet need for a consistent, reliable supply of full-length human collagen, particularly for breakthrough applications in healthcare and longevity sectors.”

“Once we achieve key milestones in this strategic segment, we plan to scale our efforts into broader markets, fulfilling our commitment to sustainable solutions. By doing so, we aim to reduce environmental impact and enhance the quality of life for all,” she added.

Collagen
© Jellatech

The most unique protein in mammals

Founded in 2020 by Michelsen in Raleigh, North Carolina, Jellatech uses cellular agriculture to produce complex proteins at scale, specifically bio-identical bovine, porcine, and human cell-based collagen.

According to Jellatech, collagen is the most unique and abundant protein in mammals, characterized by its triple-helical structure that provides essential support to cells and tissues. Its versatility has led to widespread use across various industries, from healthcare to personal care to biomedical research or F&B.

However, since it is sourced from animals, collagen production faces sustainability demands and supply chain challenges, prompting companies to seek innovative alternatives.

Jellatech positions itself as a solution to these hurdles, offering a novel source for collagen that is ethical, sustainable, and risk-free from animal diseases and, most importantly, can be scalable to supply global markets.

Support from investors

Last year, the biotech raised $3.5 million in an oversubscribed seed round to scale its manufacturing platform and introduce cell-based proteins to the global market. The round was led by the Nordic-based VC firm byFounders, with participation from Milano Investment Partners, Joyful VC, Siddhi Capital, Blustein, and others.

“At Jellatech, we are committed to advancing health, quality of life, and biomedical innovations through our unique cell-based technology”

Additionally, in 2021, the company secured $2 million to develop its proteins, and in 2022, it received a strategic investment from the VC firm CULT Food Sciences. Jellatech is also a partner of the newly launched Bezos Center for Sustainable Protein at North Carolina State University.

“At Jellatech, we are committed to advancing health, quality of life, and biomedical innovations through our unique cell-based technology. With our new platform, you can now explore how our technology is transforming industries and improving lives,” the biotech startup said in the announcement.

Share

Interviews